| Symbol | RCUS |
|---|---|
| Name | ARCUS BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3928 POINT EDEN WAY, HAYWARD, California, 94545, United States |
| Telephone | +1 510 694-6200 |
| Fax | — |
| — | |
| Website | https://www.arcusbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001724521 |
| Description | Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Additional info from NASDAQ: |
2026-07-01 15:00
New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
Read more
2026-06-24 22:17
📋 Juan Jaen (Officer) plans to sell 50K shares of Arcus Biosciences, Inc. (at $28.80 each, total $1.4M) Filed: Jun 24, 2026 | ID: 000402
Read more
2026-06-24 21:41
Jaen Juan C. 🔴 sold 31.4K shares of Arcus Biosciences, Inc. (RCUS) at $29.66 Transaction Date: Jun 22, 2026 | Filing ID: 000294
Read more
2026-06-22 22:31
📋 Juan Jaen (Officer) plans to sell 25K shares of Arcus Biosciences, Inc. (at $27.23 each, total $681K) Filed: Jun 22, 2026 | ID: 000398
Read more
2026-06-12 20:28
Director Lambert Nicole 🟢 acquired 22.6K shares (1 derivative) of Arcus Biosciences, Inc. (RCUS) at $23.30 Transaction Date: Jun 11, 2026 | Filing ID: 000003
Read more
2026-06-12 20:28
Director Machado Patrick 🟢 acquired 22.6K shares (1 derivative) of Arcus Biosciences, Inc. (RCUS) at $23.30 Transaction Date: Jun 11, 2026 | Filing ID: 000003
Read more
2026-06-12 20:28
Director KANEKO YASUNORI 🟢 acquired 22.6K shares (1 derivative) of Arcus Biosciences, Inc. (RCUS) at $23.30 Transaction Date: Jun 11, 2026 | Filing ID: 000003
Read more
2026-06-12 20:28
Director FALBERG KATHRYN E 🟢 acquired 22.6K shares (1 derivative) of Arcus Biosciences, Inc. (RCUS) at $23.30 Transaction Date: Jun 11, 2026 | Filing ID: 000009
Read more
2026-06-12 20:27
Director Ribas Antoni 🟢 acquired 22.6K shares (1 derivative) of Arcus Biosciences, Inc. (RCUS) at $23.30 Transaction Date: Jun 11, 2026 | Filing ID: 000006
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07667335 | Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unrese… | Phase1 | Locally Advanced Bladder Urothelial Carcinoma | Not_Yet_Recruiting | 2026-12-01 | 2029-07-16 | ClinicalTrials.gov |
| NCT07662057 | A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Par… | Phase1 | Healthy Volunteers | Not_Yet_Recruiting | 2026-07-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT07641881 | A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect … | Phase1 | Healthy Participants | Recruiting | 2026-05-29 | 2026-07-01 | ClinicalTrials.gov |
| NCT07397611 | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC | Phase2 | Renal Cell Carcinoma | Recruiting | 2026-03-09 | 2029-09-30 | ClinicalTrials.gov |
| NCT07364214 | Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult… | Phase1 | Healthy Participants | Completed | 2026-02-03 | 2026-04-06 | ClinicalTrials.gov |
| NCT07283848 | Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma | Phase2 | Adenocarcinoma Stomach | Withdrawn | 2026-02-01 | 2029-12-01 | ClinicalTrials.gov |
| NCT07011719 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patient… | Phase3 | Metastatic Clear Cell Renal Cell Carcinoma | Recruiting | 2025-09-08 | 2030-12-01 | ClinicalTrials.gov |
| NCT07000149 | A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs N… | Phase3 | Advanced Clear Cell Renal Cell Carcinoma | Active_Not_Recruiting | 2025-07-28 | 2032-07-29 | ClinicalTrials.gov |
| NCT06919991 | Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) | Phase1 | Healthy Participants | Completed | 2025-05-02 | 2025-10-18 | ClinicalTrials.gov |
| NCT06727565 | Study of Novel Treatment Combination Therapies in Participants With Head and Ne… | Phase2 | Head and Neck Squamous Cell Carcinoma | Active_Not_Recruiting | 2025-02-18 | 2026-08-01 | ClinicalTrials.gov |
| NCT06608927 | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Pati… | Phase3 | Metastatic Pancreatic Ductal Adenocarcinoma | Active_Not_Recruiting | 2024-12-13 | 2030-11-30 | ClinicalTrials.gov |
| NCT06048484 | Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma | Phase2 | Pancreatic Ductal Adenocarcinoma | Recruiting | 2024-05-10 | 2027-04-01 | ClinicalTrials.gov |
| NCT06048133 | Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of… | Phase2 | Biliary Tract Carcinoma | Active_Not_Recruiting | 2024-03-08 | 2027-07-01 | ClinicalTrials.gov |
| NCT06191796 | Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in… | Phase1 | Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | Terminated | 2024-01-25 | 2025-05-12 | ClinicalTrials.gov |
| NCT06120075 | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advan… | Phase1 | Advanced Cancer | Active_Not_Recruiting | 2024-01-19 | 2026-11-01 | ClinicalTrials.gov |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibit… | Phase1 | Head and Neck Cancer | Withdrawn | 2023-12-31 | 2026-12-01 | ClinicalTrials.gov |
| NCT06004921 | A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 i… | Phase1 | Cancer | Completed | 2023-10-16 | 2024-02-23 | ClinicalTrials.gov |
| NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advance… | Phase1 | Advanced Cancer | Active_Not_Recruiting | 2023-10-13 | 2027-09-01 | ClinicalTrials.gov |
| NCT05999513 | A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adul… | Phase1 | Healthy Participants | Completed | 2023-08-21 | 2023-10-31 | ClinicalTrials.gov |
| NCT05915442 | Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Se… | Phase2 | Oligometastatic Prostate Cancer | Recruiting | 2023-07-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT05724563 | Domvanalimab and Zimberelimab in Advanced Liver Cancers | Phase2 | Hepatobiliary Cancer | Active_Not_Recruiting | 2023-06-12 | 2029-12-31 | ClinicalTrials.gov |
| NCT05688215 | Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatme… | Phase1 | Borderline Resectable Pancreatic Adenocarcinoma | Recruiting | 2023-03-07 | 2027-03-02 | ClinicalTrials.gov |
| NCT05419479 | Switch Maintenance in Pancreatic | Phase1 | Pancreatic Cancer | Suspended | 2022-11-30 | 2032-05-17 | ClinicalTrials.gov |
| NCT05568095 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab,… | Phase3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | Active_Not_Recruiting | 2022-11-21 | 2026-06-01 | ClinicalTrials.gov |
| NCT05536141 | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Ca… | Phase1 | Clear Cell Renal Cell Carcinoma | Recruiting | 2022-10-26 | 2029-03-01 | ClinicalTrials.gov |
| NCT05502237 | Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembroliz… | Phase3 | Non-small Cell Lung Cancer | Active_Not_Recruiting | 2022-10-12 | 2029-01-01 | ClinicalTrials.gov |
| NCT05329766 | A Safety and Efficacy Study of Treatment Combinations With and Without Chemothe… | Phase2 | Gastrointestinal Tract Malignancies | Active_Not_Recruiting | 2022-06-10 | 2027-06-01 | ClinicalTrials.gov |
| NCT05411146 | A Study Investigating the Safety, Absorption, and Elimination of Radioactively … | Phase1 | Healthy Participants | Completed | 2022-05-25 | 2022-07-07 | ClinicalTrials.gov |
| NCT05024097 | A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine… | Phase2 | Rectal Cancer | Recruiting | 2022-03-31 | 2030-12-01 | ClinicalTrials.gov |
| NCT05130177 | Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed… | Phase2 | Melanoma | Active_Not_Recruiting | 2022-03-16 | 2030-01-31 | ClinicalTrials.gov |
| NCT05277012 | A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Fo… | Phase1 | Healthy Participants | Completed | 2022-02-10 | 2022-03-31 | ClinicalTrials.gov |
| NCT05117554 | Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With… | Phase1 | Healthy Participants | Completed | 2021-11-09 | 2023-02-17 | ClinicalTrials.gov |
| NCT05154136 | A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pha… | Phase1 | Healthy Participants | Completed | 2021-10-20 | 2021-12-10 | ClinicalTrials.gov |
| NCT04791839 | Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (A… | Phase2 | Non Small Cell Lung Cancer | Active_Not_Recruiting | 2021-08-04 | 2030-12-31 | ClinicalTrials.gov |
| NCT04660812 | An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) … | Phase1 | Metastatic Colorectal Cancer | Completed | 2021-05-10 | 2025-09-05 | ClinicalTrials.gov |
| NCT04656535 | AB154 Combined With AB122 for Recurrent Glioblastoma | Early_Phase1 | Glioblastoma | Active_Not_Recruiting | 2021-04-21 | 2026-12-31 | ClinicalTrials.gov |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanc… | Phase1 | Advanced Solid Tumor | Completed | 2021-03-19 | 2025-08-25 | ClinicalTrials.gov |
| NCT04736173 | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in L… | Phase2 | Non Small Cell Lung Cancer | Active_Not_Recruiting | 2021-02-08 | 2027-05-01 | ClinicalTrials.gov |
| NCT04575311 | A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Vol… | Phase1 | Healthy Volunteers | Completed | 2020-10-20 | 2021-09-22 | ClinicalTrials.gov |
| NCT04381832 | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resis… | Phase1 | Prostatic Neoplasms, Castration-Resistant | Completed | 2020-07-07 | 2024-08-30 | ClinicalTrials.gov |
| NCT04262856 | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants W… | Phase2 | Non Small Cell Lung Cancer | Completed | 2020-05-28 | 2025-07-09 | ClinicalTrials.gov |
| NCT04104672 | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With G… | Phase1 | Advanced Pancreatic Cancer | Active_Not_Recruiting | 2019-11-06 | 2027-05-01 | ClinicalTrials.gov |
| NCT04087018 | Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected P… | Phase1 | Advanced Solid Tumors | Completed | 2019-09-24 | 2024-06-17 | ClinicalTrials.gov |
| NCT03846310 | A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer | Phase1 | Non Small Cell Lung Cancer Metastatic | Completed | 2019-04-01 | 2024-11-18 | ClinicalTrials.gov |
| NCT03720678 | A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointes… | Phase1 | GastroEsophageal Cancer | Completed | 2018-11-18 | 2021-06-25 | ClinicalTrials.gov |
| NCT03677973 | A Study to Investigate the Safety of AB680 in Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2018-10-16 | 2019-08-19 | ClinicalTrials.gov |
| NCT03719326 | A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Partic… | Phase1 | TNBC - Triple-Negative Breast Cancer | Completed | 2018-10-15 | 2021-07-02 | ClinicalTrials.gov |
| NCT03628677 | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With A… | Phase1 | Solid Tumor, Unspecified, Adult | Completed | 2018-09-12 | 2025-01-23 | ClinicalTrials.gov |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations i… | Phase1 | Non-small Cell Lung Cancer | Completed | 2018-07-24 | 2021-09-03 | ClinicalTrials.gov |
Total clinical trials: 49
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Quemliclustat | Other | Phase PHASE2 | Biliary Tract Carcinoma | ACTIVE_NOT_RECRUITING | NCT06048133 |
| Zimberelimab | Other | Phase PHASE2 | Biliary Tract Carcinoma | ACTIVE_NOT_RECRUITING | NCT06048133 |
| Cisplatin | Other | Phase PHASE2 | Biliary Tract Carcinoma | ACTIVE_NOT_RECRUITING | NCT06048133 |
| Gemcitabine | Other | Phase PHASE2 | Biliary Tract Carcinoma | ACTIVE_NOT_RECRUITING | NCT06048133 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Domvanalimab | Other | Phase PHASE2 | Hepatobiliary Cancer | ACTIVE_NOT_RECRUITING | NCT05724563 |
| Zimberelimab | Other | Phase PHASE2 | Hepatobiliary Cancer | ACTIVE_NOT_RECRUITING | NCT05724563 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Nab-paclitaxel | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| AB680 | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Gemcitabine | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Nab-paclitaxel | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Placebo | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Quemliclustat | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Oxaliplatin | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Leucovorin | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Fluorouracil | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| AB598 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07662057 |
| AB102 | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07662057 |
| Biopsy Procedure | Procedure | Phase PHASE1 | Locally Advanced Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07667335 |
| Pembrolizumab | Other | Phase PHASE1 | Locally Advanced Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07667335 |
| Magnetic Resonance Imaging | Other | Phase PHASE1 | Locally Advanced Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07667335 |
| Enfortumab Vedotin | Other | Phase PHASE1 | Locally Advanced Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07667335 |
| Computed Tomography | Other | Phase PHASE1 | Locally Advanced Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07667335 |
| Biospecimen Collection | Other | Phase PHASE1 | Locally Advanced Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07667335 |
| Quemliclustat | Other | Phase PHASE1 | Locally Advanced Bladder Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07667335 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07662057 |
| AB102 | Other | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07662057 |
| Domvanalimab | Other | Phase PHASE2 | Hepatobiliary Cancer | ACTIVE_NOT_RECRUITING | NCT05724563 |
| Zimberelimab | Other | Phase PHASE2 | Hepatobiliary Cancer | ACTIVE_NOT_RECRUITING | NCT05724563 |
| Casdatifan | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07641881 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT04262856 |
| Etrumadenant | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT04262856 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT04262856 |
| Casdatifan | Other | Phase PHASE1 | Healthy Participants | NOT_YET_RECRUITING | NCT07641881 |
| Casdatifan | Other | Phase PHASE1 | Healthy Participants | NOT_YET_RECRUITING | NCT07641881 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT04262856 |
| Etrumadenant | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT04262856 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT04262856 |
| Etrumadenant | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Oxaliplatin | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Leucovorin | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Fluorouracil | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| AB598 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| FOLFIRI | Other | Phase PHASE1 | Pancreatic Cancer | SUSPENDED | NCT05419479 |
| APX005M | Other | Phase PHASE1 | Pancreatic Cancer | SUSPENDED | NCT05419479 |
| DOMVANALIMAB | Other | Phase PHASE1 | Pancreatic Cancer | SUSPENDED | NCT05419479 |
| ZIMBERELIMAB | Other | Phase PHASE1 | Pancreatic Cancer | SUSPENDED | NCT05419479 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Nivolumab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Oxaliplatin | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Leucovorin | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Fluorouracil | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Capecitabine | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Zimberelimab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Domvanalimab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Gemcitabine | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Nab-paclitaxel | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Placebo | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Quemliclustat | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Nab-paclitaxel | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| AB680 | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Quemliclustat | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Oxaliplatin | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Leucovorin Calcium | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Leucovorin | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Irinotecan | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Fluorouracil | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Core Biopsy | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Computed Tomography | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Biospecimen Collection | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Zimberelimab | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Quemliclustat | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Oxaliplatin | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Leucovorin Calcium | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Leucovorin | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Irinotecan | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Fluorouracil | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Core Biopsy | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Computed Tomography | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Biospecimen Collection | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Zimberelimab | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Quemliclustat | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Oxaliplatin | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Leucovorin Calcium | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Leucovorin | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Irinotecan | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Fluorouracil | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Core Biopsy | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Computed Tomography | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Biospecimen Collection | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Zimberelimab | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Quemliclustat | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Oxaliplatin | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Leucovorin Calcium | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Leucovorin | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Irinotecan | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Fluorouracil | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Core Biopsy | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Computed Tomography | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Biospecimen Collection | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Zimberelimab | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Quemliclustat | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Oxaliplatin | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Leucovorin Calcium | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Leucovorin | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Irinotecan | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Fluorouracil | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Core Biopsy | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Computed Tomography | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Biospecimen Collection | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Nivolumab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Oxaliplatin | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Leucovorin | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Fluorouracil | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Capecitabine | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Zimberelimab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Domvanalimab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Gemcitabine | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Nab-paclitaxel | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Placebo | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Quemliclustat | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Nivolumab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Oxaliplatin | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Leucovorin | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Fluorouracil | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Capecitabine | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Zimberelimab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Domvanalimab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Gemcitabine | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Nab-paclitaxel | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Placebo | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Quemliclustat | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Nab-paclitaxel | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| AB680 | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Nivolumab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Oxaliplatin | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Leucovorin | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Fluorouracil | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Capecitabine | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Zimberelimab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Domvanalimab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Gemcitabine | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Nab-paclitaxel | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Placebo | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Quemliclustat | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Nab-paclitaxel | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| AB680 | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Nivolumab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Oxaliplatin | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Leucovorin | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Fluorouracil | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Capecitabine | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Zimberelimab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Domvanalimab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Gemcitabine | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Nab-paclitaxel | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Placebo | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Quemliclustat | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Nab-paclitaxel | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| AB680 | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Nivolumab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Oxaliplatin | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Leucovorin | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Fluorouracil | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Capecitabine | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Zimberelimab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Domvanalimab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Gemcitabine | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Nab-paclitaxel | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Placebo | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Quemliclustat | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Nab-paclitaxel | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| AB680 | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Nab-paclitaxel | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| AB680 | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Nab-paclitaxel | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| AB680 | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Etrumadenant | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Etrumadenant | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Etrumadenant | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Etrumadenant | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Etrumadenant | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Etrumadenant | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Etrumadenant | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Etrumadenant | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Radiation | Other | Phase PHASE1 | Head and Neck Cancer | WITHDRAWN | NCT04892875 |
| Cisplatin | Other | Phase PHASE1 | Head and Neck Cancer | WITHDRAWN | NCT04892875 |
| Etrumadenant | Other | Phase PHASE1 | Head and Neck Cancer | WITHDRAWN | NCT04892875 |
| Zimberelimab | Other | Phase PHASE1 | Head and Neck Cancer | WITHDRAWN | NCT04892875 |
| zimberelimab | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT04087018 |
| [14C]-etrumadenant | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05411146 |
| Etrumadenant | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05277012 |
| Itraconazole | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05154136 |
| Etrumadenant | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05154136 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04575311 |
| AB680 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04575311 |
| mFOLFOX | Other | Phase PHASE1 | GastroEsophageal Cancer | COMPLETED | NCT03720678 |
| etrumadenant | Other | Phase PHASE1 | GastroEsophageal Cancer | COMPLETED | NCT03720678 |
| nanoparticle albumin-bound paclitaxel (NP) | Other | Phase PHASE1 | TNBC - Triple-Negative Breast Cancer | COMPLETED | NCT03719326 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE1 | TNBC - Triple-Negative Breast Cancer | COMPLETED | NCT03719326 |
| IPI-549 | Other | Phase PHASE1 | TNBC - Triple-Negative Breast Cancer | COMPLETED | NCT03719326 |
| Etrumadenant | Other | Phase PHASE1 | TNBC - Triple-Negative Breast Cancer | COMPLETED | NCT03719326 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03677973 |
| AB680 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03677973 |
| Zimberelimab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | COMPLETED | NCT03629756 |
| Etrumadenant | Other | Phase PHASE1 | Non-small Cell Lung Cancer | COMPLETED | NCT03629756 |
| Placebo | Other | Phase PHASE1 | Cancer | COMPLETED | NCT06004921 |
| AB801 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT06004921 |
| casdatifan | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05999513 |
| Midazolam | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05117554 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05117554 |
| casdatifan | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05117554 |
| Pembrolizumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer Metastatic | COMPLETED | NCT03846310 |
| Pemetrexed | Other | Phase PHASE1 | Non Small Cell Lung Cancer Metastatic | COMPLETED | NCT03846310 |
| Carboplatin | Other | Phase PHASE1 | Non Small Cell Lung Cancer Metastatic | COMPLETED | NCT03846310 |
| Zimberelimab | Other | Phase PHASE1 | Non Small Cell Lung Cancer Metastatic | COMPLETED | NCT03846310 |
| Etrumadenant | Other | Phase PHASE1 | Non Small Cell Lung Cancer Metastatic | COMPLETED | NCT03846310 |
| Zimberelimab | Other | Phase PHASE1 | Solid Tumor, Unspecified, Adult | COMPLETED | NCT03628677 |
| Domvanalimab | Other | Phase PHASE1 | Solid Tumor, Unspecified, Adult | COMPLETED | NCT03628677 |
| Etrumadenant | Other | Phase PHASE2 | Prostate Adenocarcinoma | RECRUITING | NCT03821246 |
| Tocilizumab | Other | Phase PHASE2 | Prostate Adenocarcinoma | RECRUITING | NCT03821246 |
| Atezolizumab | Other | Phase PHASE2 | Prostate Adenocarcinoma | RECRUITING | NCT03821246 |
| Stereotactic Body Radiation Therapy | Drug | Phase PHASE2 | Oligometastatic Prostate Cancer | RECRUITING | NCT05915442 |
| Zimberelimab | Other | Phase PHASE2 | Oligometastatic Prostate Cancer | RECRUITING | NCT05915442 |
| Etrumadenant | Other | Phase PHASE2 | Oligometastatic Prostate Cancer | RECRUITING | NCT05915442 |
| Quemliclustat | Other | Phase PHASE2 | Oligometastatic Prostate Cancer | RECRUITING | NCT05915442 |
| Domvanalimab | Other | Phase PHASE2 | Hepatobiliary Cancer | ACTIVE_NOT_RECRUITING | NCT05724563 |
| Zimberelimab | Other | Phase PHASE2 | Hepatobiliary Cancer | ACTIVE_NOT_RECRUITING | NCT05724563 |
| Nivolumab | Other | Phase PHASE1 | Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | TERMINATED | NCT06191796 |
| AB521 | Other | Phase PHASE1 | Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | TERMINATED | NCT06191796 |
| zanzalintinib | Other | Phase PHASE1 | Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | TERMINATED | NCT06191796 |
| Docetaxel | Other | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | COMPLETED | NCT04381832 |
| Enzalutamide | Other | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | COMPLETED | NCT04381832 |
| Quemliclustat | Other | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | COMPLETED | NCT04381832 |
| Zimberelimab | Other | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | COMPLETED | NCT04381832 |
| Etrumadenant | Other | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | COMPLETED | NCT04381832 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT04262856 |
| Etrumadenant | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT04262856 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT04262856 |
| Zimberelimab (AB122) | Other | Phase PHASE2 | Rectal Cancer | RECRUITING | NCT05024097 |
| FOLFOX regimen | Other | Phase PHASE2 | Rectal Cancer | RECRUITING | NCT05024097 |
| Radiation therapy | Drug | Phase PHASE2 | Rectal Cancer | RECRUITING | NCT05024097 |
| Etrumadenant (AB928) | Other | Phase PHASE2 | Rectal Cancer | RECRUITING | NCT05024097 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04772989 |
| AB308 | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04772989 |
| Regorafenib | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT04660812 |
| m-FOLFOX-6 regimen | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT04660812 |
| Bevacizumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT04660812 |
| Zimberelimab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT04660812 |
| Etrumadenant | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT04660812 |
| AB680 | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT04660812 |
| Nivolumab | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Docetaxel | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Nab-paclitaxel | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Paclitaxel | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Pemetrexed | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Cisplatin | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Carboplatin | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Etrumadenant (ETRUMA) | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Sacituzumab govitecan-hziy (SG) | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Domvanalimab (DOM) | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Zimberelimab (ZIM) | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Platinum-Based Doublet | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05676931 |
| Docetaxel | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05676931 |
| Zimberelimab | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05676931 |
| Quemliclustat | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05676931 |
| Domvanalimab | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05676931 |
| Etrumadenant | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04791839 |
| Phenytoin | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06919991 |
| Itraconazole | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06919991 |
| Casdatifan | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06919991 |
| FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) | Other | Phase PHASE2 | Adenocarcinoma Stomach | WITHDRAWN | NCT07283848 |
| Domvanalimab | Other | Phase PHASE2 | Adenocarcinoma Stomach | WITHDRAWN | NCT07283848 |
| Zimberelimab | Other | Phase PHASE2 | Adenocarcinoma Stomach | WITHDRAWN | NCT07283848 |
| Zimberelimab | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Quemliclustat | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Oxaliplatin | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Leucovorin Calcium | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Leucovorin | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Irinotecan | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Fluorouracil | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Core Biopsy | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Computed Tomography | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Biospecimen Collection | Other | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Quemliclustat | Other | Phase PHASE2 | Biliary Tract Carcinoma | RECRUITING | NCT06048133 |
| Zimberelimab | Other | Phase PHASE2 | Biliary Tract Carcinoma | RECRUITING | NCT06048133 |
| Cisplatin | Other | Phase PHASE2 | Biliary Tract Carcinoma | RECRUITING | NCT06048133 |
| Gemcitabine | Other | Phase PHASE2 | Biliary Tract Carcinoma | RECRUITING | NCT06048133 |
| Pemetrexed | Other | Phase PHASE3 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05502237 |
| Nab-paclitaxel | Other | Phase PHASE3 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05502237 |
| Paclitaxel | Other | Phase PHASE3 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05502237 |
| Cisplatin | Other | Phase PHASE3 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05502237 |
| Carboplatin | Other | Phase PHASE3 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05502237 |
| Pembrolizumab | Other | Phase PHASE3 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05502237 |
| Domvanalimab | Other | Phase PHASE3 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05502237 |
| Zimberelimab | Other | Phase PHASE3 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05502237 |
| FOLFIRI | Other | Phase PHASE1 | Pancreatic Cancer | SUSPENDED | NCT05419479 |
| APX005M | Other | Phase PHASE1 | Pancreatic Cancer | SUSPENDED | NCT05419479 |
| DOMVANALIMAB | Other | Phase PHASE1 | Pancreatic Cancer | SUSPENDED | NCT05419479 |
| ZIMBERELIMAB | Other | Phase PHASE1 | Pancreatic Cancer | SUSPENDED | NCT05419479 |
| Modified FOLFIRINOX | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06048484 |
| Etrumadenant | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06048484 |
| Quemliclustat | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06048484 |
| Zimberelimab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06048484 |
| Stereotactic body radiotherapy (SBRT) | Drug | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06048484 |
| Carboplatin | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06727565 |
| Paclitaxel | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06727565 |
| Zimberelimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06727565 |
| Domvanalimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06727565 |
| Quemliclustat | Other | Phase PHASE1 | Healthy Participants | ACTIVE_NOT_RECRUITING | NCT07364214 |
| Ipilimumab | Other | Phase PHASE3 | Advanced Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT07000149 |
| Nivolumab | Other | Phase PHASE3 | Advanced Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT07000149 |
| Casdatifan | Other | Phase PHASE3 | Advanced Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT07000149 |
| Volrustomig | Other | Phase PHASE3 | Advanced Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT07000149 |
| Zimberelimab | Other | Phase PHASE2 | Renal Cell Carcinoma | RECRUITING | NCT07397611 |
| Casdatifan | Other | Phase PHASE2 | Renal Cell Carcinoma | RECRUITING | NCT07397611 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Oxaliplatin | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Leucovorin | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Fluorouracil | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| AB598 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Domvanalimab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05130177 |
| Zimberelimab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05130177 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Nab-paclitaxel | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| AB680 | Other | Phase PHASE1 | Advanced Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04104672 |
| Gemcitabine | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Nab-paclitaxel | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Placebo | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Quemliclustat | Other | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Nivolumab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Oxaliplatin | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Leucovorin | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Fluorouracil | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Capecitabine | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Zimberelimab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Domvanalimab | Other | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Placebo | Other | Phase EARLY_PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT04656535 |
| Domvanalimab | Other | Phase EARLY_PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT04656535 |
| Zimberelimab | Other | Phase EARLY_PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT04656535 |
| Placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Domvanalimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Durvalumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Quemliclustat | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07364214 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Quemliclustat | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07364214 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Quemliclustat | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07364214 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Quemliclustat | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07364214 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Quemliclustat | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07364214 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Quemliclustat | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07364214 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Quemliclustat | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07364214 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Quemliclustat | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07364214 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Quemliclustat | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07364214 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Quemliclustat | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07364214 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Quemliclustat | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07364214 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Docetaxel | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| AB801 | Other | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Quemliclustat | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07364214 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Oxaliplatin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Leucovorin | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Fluorouracil | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Zimberelimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Quemliclustat | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Domvanalimab | Other | Phase PHASE2 | Gastrointestinal Tract Malignancies | ACTIVE_NOT_RECRUITING | NCT05329766 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Ipilimumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Zimberelimab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| casdatifan | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05536141 |
| Placebo | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Casdatifan | Other | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| Placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Domvanalimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Durvalumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Domvanalimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Durvalumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Domvanalimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Durvalumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Domvanalimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Durvalumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Domvanalimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Durvalumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Domvanalimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Durvalumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Domvanalimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Durvalumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Domvanalimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Durvalumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Domvanalimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Durvalumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Pembrolizumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Pemetrexed | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Zimberelimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Domvanalimab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04736173 |
| Placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Domvanalimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Durvalumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Placebo | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Domvanalimab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Durvalumab | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| Placebo | Other | Phase EARLY_PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT04656535 |
| Domvanalimab | Other | Phase EARLY_PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT04656535 |
| Zimberelimab | Other | Phase EARLY_PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT04656535 |
| FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) | DRUG | Phase PHASE2 | Adenocarcinoma Stomach | WITHDRAWN | NCT07283848 |
| Volrustomig | DRUG | Phase PHASE3 | Advanced Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT07000149 |
| Phenytoin | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06919991 |
| Casdatifan | DRUG | Phase PHASE2 | Renal Cell Carcinoma | RECRUITING | NCT07397611 |
| AB521 | DRUG | Phase PHASE1 | Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | TERMINATED | NCT06191796 |
| zanzalintinib | DRUG | Phase PHASE1 | Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | TERMINATED | NCT06191796 |
| Modified FOLFIRINOX | DRUG | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06048484 |
| Stereotactic body radiotherapy (SBRT) | RADIATION | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06048484 |
| AB801 | DRUG | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Stereotactic Body Radiation Therapy | RADIATION | Phase PHASE2 | Oligometastatic Prostate Cancer | RECRUITING | NCT05915442 |
| AB598 | DRUG | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Leucovorin Calcium | DRUG | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Irinotecan | DRUG | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Core Biopsy | PROCEDURE | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Computed Tomography | PROCEDURE | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Biospecimen Collection | PROCEDURE | Phase PHASE1 | Borderline Resectable Pancreatic Adenocarcinoma | RECRUITING | NCT05688215 |
| Platinum-Based Doublet | DRUG | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05676931 |
| Etrumadenant (ETRUMA) | DRUG | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Sacituzumab govitecan-hziy (SG) | DRUG | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Domvanalimab (DOM) | DRUG | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Zimberelimab (ZIM) | DRUG | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Nivolumab | DRUG | Phase PHASE3 | Advanced Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT07000149 |
| Capecitabine | DRUG | Phase PHASE3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05568095 |
| Ipilimumab | DRUG | Phase PHASE3 | Advanced Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT07000149 |
| Cabozantinib | DRUG | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| FOLFIRI | DRUG | Phase PHASE1 | Pancreatic Cancer | SUSPENDED | NCT05419479 |
| APX005M | DRUG | Phase PHASE1 | Pancreatic Cancer | SUSPENDED | NCT05419479 |
| DOMVANALIMAB | DRUG | Phase PHASE1 | Pancreatic Cancer | SUSPENDED | NCT05419479 |
| ZIMBERELIMAB | DRUG | Phase PHASE1 | Pancreatic Cancer | SUSPENDED | NCT05419479 |
| [14C]-etrumadenant | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05411146 |
| Oxaliplatin | DRUG | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Leucovorin | DRUG | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Fluorouracil | DRUG | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT05891171 |
| Durvalumab | DRUG | Phase PHASE3 | Non-Small Cell Lung Cancer | RECRUITING | NCT05211895 |
| SRF617 | DRUG | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT05177770 |
| Itraconazole | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06919991 |
| Midazolam | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05117554 |
| casdatifan | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05999513 |
| Zimberelimab (AB122) | DRUG | Phase PHASE2 | Rectal Cancer | RECRUITING | NCT05024097 |
| FOLFOX regimen | DRUG | Phase PHASE2 | Rectal Cancer | RECRUITING | NCT05024097 |
| Radiation therapy | RADIATION | Phase PHASE2 | Rectal Cancer | RECRUITING | NCT05024097 |
| Etrumadenant (AB928) | DRUG | Phase PHASE2 | Rectal Cancer | RECRUITING | NCT05024097 |
| Radiation | RADIATION | Phase PHASE1 | Head and Neck Cancer | WITHDRAWN | NCT04892875 |
| Cisplatin | DRUG | Phase PHASE2 | Biliary Tract Carcinoma | RECRUITING | NCT06048133 |
| AB308 | DRUG | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04772989 |
| Paclitaxel | DRUG | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06727565 |
| Regorafenib | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT04660812 |
| m-FOLFOX-6 regimen | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT04660812 |
| Bevacizumab | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT04660812 |
| SG | DRUG | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | COMPLETED | NCT04381832 |
| Docetaxel | DRUG | Phase PHASE1 | Advanced Cancer | ACTIVE_NOT_RECRUITING | NCT06120075 |
| Enzalutamide | DRUG | Phase PHASE1 | Prostatic Neoplasms, Castration-Resistant | COMPLETED | NCT04381832 |
| Quemliclustat | DRUG | Phase PHASE1 | Healthy Participants | ACTIVE_NOT_RECRUITING | NCT07364214 |
| Gemcitabine | DRUG | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| Nab-paclitaxel | DRUG | Phase PHASE3 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT06608927 |
| zimberelimab | DRUG | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT05177770 |
| Pembrolizumab | DRUG | Phase PHASE3 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05502237 |
| Pemetrexed | DRUG | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05633667 |
| Carboplatin | DRUG | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06727565 |
| Tocilizumab | DRUG | Phase PHASE2 | Prostate Adenocarcinoma | RECRUITING | NCT03821246 |
| Atezolizumab | DRUG | Phase PHASE2 | Prostate Adenocarcinoma | RECRUITING | NCT03821246 |
| mFOLFOX | DRUG | Phase PHASE1 | GastroEsophageal Cancer | COMPLETED | NCT03720678 |
| etrumadenant | DRUG | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT05177770 |
| nanoparticle albumin-bound paclitaxel (NP) | DRUG | Phase PHASE1 | TNBC - Triple-Negative Breast Cancer | COMPLETED | NCT03719326 |
| Pegylated liposomal doxorubicin (PLD) | DRUG | Phase PHASE1 | TNBC - Triple-Negative Breast Cancer | COMPLETED | NCT03719326 |
| IPI-549 | DRUG | Phase PHASE1 | TNBC - Triple-Negative Breast Cancer | COMPLETED | NCT03719326 |
| Placebo | DRUG | Phase PHASE3 | Metastatic Clear Cell Renal Cell Carcinoma | RECRUITING | NCT07011719 |
| AB680 | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT04660812 |
| Etrumadenant | DRUG | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06048484 |
| Zimberelimab | DRUG | Phase PHASE2 | Renal Cell Carcinoma | RECRUITING | NCT07397611 |
| Domvanalimab | DRUG | Phase PHASE2 | Adenocarcinoma Stomach | WITHDRAWN | NCT07283848 |
Total products: 927